Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KASHIF ALI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1851423388
CMS profile
310504
Location
SILVER SPRING, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$133,301.27

246 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $64,050.63 56
GENZYME CORPORATION $40,119.56 31
AstraZeneca Pharmaceuticals LP $5,624.52 5
Janssen Biotech, Inc. $4,422.47 13
Global Blood Therapeutics, Inc. $4,116.26 7
Fresenius Kabi USA, LLC $2,550.00 1
Stemline Therapeutics Inc. $1,730.92 2
AbbVie Inc. $1,702.25 5
Heron Therapeutics, Inc. $1,400.00 1
Taiho Oncology, Inc. $1,394.12 2
Rigel Pharmaceuticals, Inc. $1,346.90 5
Novartis Pharmaceuticals Corporation $1,198.87 21
Adaptive Biotechnologies Corporation $1,000.00 1
BeiGene, Ltd. $525.00 1
Seagen Inc. $187.86 5
Boehringer Ingelheim Pharmaceuticals, Inc. $168.18 3
Merck Sharp & Dohme Corporation $150.39 10
PFIZER INC. $140.82 8
Amgen Inc. $134.74 6
Pharmacyclics LLC, An AbbVie Company $104.99 4
Secura Bio, Inc. $91.30 4
Incyte Corporation $91.18 4
Myriad Genetic Laboratories, Inc. $87.30 2
Janssen Pharmaceuticals, Inc $77.66 5
Exelixis Inc. $70.67 3
Celgene Corporation $67.09 4
Lilly USA, LLC $60.35 3
Regeneron Healthcare Solutions, Inc. $56.48 3
Dendreon Pharmaceuticals LLC $52.15 2
Takeda Pharmaceuticals U.S.A., Inc. $51.11 2
Pharmacosmos Therapeutics Inc. $47.14 2
Tactile Systems Technology Inc $44.75 3
PUMA BIOTECHNOLOGY, INC. $43.07 2
Eisai Inc. $40.32 2
Bayer HealthCare Pharmaceuticals Inc. $36.87 2
TG THERAPEUTICS, INC. $24.90 1
EMD Serono, Inc. $23.29 1
Clovis Oncology, Inc. $23.14 1
Dova Pharmaceuticals $22.80 1
Epizyme, Inc., $22.27 1
Genentech USA, Inc. $21.63 1
Kyowa Kirin, Inc. $21.28 1
Daiichi Sankyo Inc. $20.99 1
Blueprint Medicines Corporation $20.70 1
MorphoSys, US Inc. $20.32 1
Kite Pharma, Inc. $19.76 1
Acrotech Biopharma LLC $17.95 1
Alexion Pharmaceuticals, Inc. $16.51 1
ARRAY BIOPHARMA INC $14.73 1
TOLMAR Pharmaceuticals, Inc. $13.16 1
Gilead Sciences, Inc. $11.92 1

Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KASHIF ALI

NPI 1851423388 · CMS profile ID 310504

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SILVER SPRING, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1851423388?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KASHIF ALI, NPI 1851423388, CMS profile ID 310504. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851423388?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). KASHIF ALI, NPI 1851423388, CMS profile ID 310504. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851423388?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
KASHIF ALI, NPI 1851423388, CMS profile ID 310504, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1851423388?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

246 matching records · $133,301.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 246 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 246.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
BeiGene, Ltd. $525.0010/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846701631 CMS
Novartis Pharmaceuticals Corporation $83.3310/16/2021 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812583521 CMS
E.R. Squibb & Sons, L.L.C. $16.8810/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783404325 CMS
Celgene Corporation $21.9810/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783670167 CMS
E.R. Squibb & Sons, L.L.C. $2,635.0010/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783404367 CMS
Myriad Genetic Laboratories, Inc. $12.3510/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834554943 CMS
Exelixis Inc. $20.0910/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838872511 CMS
Incyte Corporation $24.3710/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835555251 CMS
E.R. Squibb & Sons, L.L.C. $300.0010/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783404377 CMS
Janssen Pharmaceuticals, Inc $7.9310/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788750845 CMS
Merck Sharp & Dohme Corporation $15.9110/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848690121 CMS
E.R. Squibb & Sons, L.L.C. $125.0510/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783404335 CMS
E.R. Squibb & Sons, L.L.C. $1,650.0010/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783404341 CMS
Amgen Inc. $21.4410/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826372441 CMS
Myriad Genetic Laboratories, Inc. $74.9510/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834554939 CMS
E.R. Squibb & Sons, L.L.C. $82.1609/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783404351 CMS
E.R. Squibb & Sons, L.L.C. $1,059.0509/29/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783404353 CMS
GENZYME CORPORATION $16.1609/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843594843 CMS
E.R. Squibb & Sons, L.L.C. $14.1309/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783404329 CMS
PUMA BIOTECHNOLOGY, INC. $20.4409/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834088873 CMS
AbbVie Inc. $23.5009/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793850809 CMS
ARRAY BIOPHARMA INC $14.7309/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833183671 CMS
Daiichi Sankyo Inc. $20.9909/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836322237 CMS
Novartis Pharmaceuticals Corporation $99.7009/16/2021 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812583519 CMS
Regeneron Healthcare Solutions, Inc. $13.7009/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809554691 CMS
PFIZER INC. $21.3509/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832841591 CMS
PFIZER INC. $13.1709/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832870941 CMS
TG THERAPEUTICS, INC. $24.9009/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844043041 CMS
Janssen Biotech, Inc. $26.8209/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788750827 CMS
E.R. Squibb & Sons, L.L.C. $22.1909/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783404313 CMS
Janssen Biotech, Inc. $7.2109/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788750833 CMS
Janssen Biotech, Inc. $8.7609/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788750835 CMS
Novartis Pharmaceuticals Corporation $18.0609/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812583497 CMS
Janssen Biotech, Inc. $1,560.0008/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788750825 CMS
Pharmacyclics LLC, An AbbVie Company $29.7508/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781007651 CMS
Amgen Inc. $20.3108/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826372437 CMS
GENZYME CORPORATION $14.9608/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843594825 CMS
GENZYME CORPORATION $14.9208/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843594829 CMS
Janssen Biotech, Inc. $1,160.0008/18/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788750831 CMS
Secura Bio, Inc. $18.6308/18/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 851659277 CMS
Tactile Systems Technology Inc $14.9208/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 757097192 CMS
Novartis Pharmaceuticals Corporation $18.9608/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812583499 CMS
Novartis Pharmaceuticals Corporation $99.7008/16/2021 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812583517 CMS
Seagen Inc. $95.0008/16/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832149395 CMS
Alexion Pharmaceuticals, Inc. $16.5108/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783113369 CMS
Novartis Pharmaceuticals Corporation $24.0708/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812583495 CMS
Merck Sharp & Dohme Corporation $13.7908/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848375661 CMS
Secura Bio, Inc. $40.1108/03/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 851659273 CMS
GENZYME CORPORATION $14.6907/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843594801 CMS
PFIZER INC. $18.2807/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832615893 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $96,857.80 242
PY2020 $24,496.91 200
PY2021 $133,301.27 246
PY2022 $197,546.09 282
PY2023 $168,322.64 274
PY2024 $221,790.02 302
PY2025 $144,918.86 277

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $75,711.75 48
PY2024 Principal investigator $78,113.05 29
PY2023 Principal investigator $31,721.46 66
PY2022 Recipient $13,000.00 18
PY2022 Principal investigator $70,583.15 17
PY2021 Principal investigator $93,784.00 13
PY2020 Principal investigator $8,500.00 2
PY2019 Principal investigator $200.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233740484
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233740482
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742522
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,275.00 10/31/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185539049
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233740480
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742517
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742519
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742515
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233740462
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233740464
Principal investigator 1 Amgen Inc. $33.34 08/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium No dispute reported 06/30/2026 1246643838
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174942189
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942214
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942277
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174942291
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742509
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742511
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742513
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233740466
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 07/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174942226
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233740468
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 06/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174942239
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 06/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174942253
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/31/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233740470
Principal investigator 1 Amgen Inc. $166.70 05/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
MyLung Consortium Study (USOR) No dispute reported 06/30/2026 1246643842
Principal investigator 1 Ipsen Bioscience Inc. $1,000.00 05/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176544953
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174942154
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174942165
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174942267
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174942303
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174942338
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 04/30/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233740472
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,100.00 04/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742499
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 04/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942315
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,100.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742501
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 03/31/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233740474
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 03/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942177
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,100.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742503
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $18,500.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742505
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,500.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742507
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 02/28/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233740476
Principal investigator 1 Janssen Research & Development, LLC $1,125.00 02/12/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Silver Spg White Oak Ca
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175230394
Principal investigator 1 Janssen Research & Development, LLC $1,125.00 02/12/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Silver Spg White Oak Ca
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175230405
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 01/31/2025 Non-covered Recipient Entity
Maryland Oncology Hematology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233740478
Principal investigator 1 AstraZeneca UK Limited $10,950.00 01/27/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients with EGFRm, Metastatic NSCLC who have Progressed Extracranially following First-Line Osimertinib Therapy (COMPEL) No dispute reported 06/30/2026 1185539045
Principal investigator 1 AstraZeneca Pharmaceuticals LP $520.00 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 1185539047
Principal investigator 1 Eli Lilly and Company $433.33 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY PA
Not supplied No dispute reported 06/30/2026 1187885770
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 01/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematlgy Columbia
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942327